Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer

BACKGROUND: Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC). The aim of this study was to evaluate the efficacy and safety of this regimen in combination with bevacizumab (BV), as first-line treatment for m...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: García-Alfonso, P, Muñoz-Martin, A J, Alvarez-Suarez, S, Jerez-Gilarranz, Y, Riesco-Martinez, M, Khosravi, P, Martin, M
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2010
Ämnen:
Clinical Study
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2990572/
https://ncbi.nlm.nih.gov/pubmed/20978503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605907
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk